Vireo Growth (VREOD) and Its Competitors Critical Analysis

Vireo Growth (OTCMKTS:VREOD – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Vireo Growth to related businesses based on the strength of its valuation, dividends, earnings, risk, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vireo Growth and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vireo Growth 1 0 0 0 1.00
Vireo Growth Competitors 7844 13796 25806 1039 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.69%. Given Vireo Growth’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Vireo Growth and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Vireo Growth $268.77 million -$68.11 million -3.02
Vireo Growth Competitors $3.55 billion $3.17 billion 562.76

Vireo Growth’s competitors have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -0.04, suggesting that their average stock price is 104% less volatile than the S&P 500.

Profitability

This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vireo Growth -23.37% -19.76% -7.15%
Vireo Growth Competitors -2,398.26% -203.62% -15.08%

Summary

Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

(Get Free Report)

Vireo Growth is a U.S. cannabis company that cultivates, processes and sells cannabis products through licensed operations and retail dispensaries. Its products include cannabis flower and other consumer cannabis offerings, with availability and product types varying by state. The company was formerly known as Goodness Growth Holdings and has roots in Vireo Health, a medical cannabis business. It serves multiple U.S. markets, including Minnesota and New York, as well as other states where it holds licensed operations.

Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.